Puma Cash And Short Term Investments from 2010 to 2026
| PBYI Stock | USD 6.06 -0.16 -2.57% |
Cash And Short Term Investments | First Reported 2007-09-30 | Previous Quarter 94.4 M | Current Value 97.5 M | Quarterly Volatility 67.4 M |
Macro event markers
Review Puma Biotechnology financial statements over time to add context on performance and capital structure. Key drivers include Interest Expense of 5.8 M, Other Operating Expenses of 181.4 M or Operating Income of 39.2 M along with ratios such as Price To Sales Ratio of 1.37, Dividend Yield of 0.0 or PTB Ratio of 2.17. This view complements Puma Biotechnology Valuation and Volatility modules.
Puma | Cash And Short Term Investments | Build AI portfolio with Puma Stock |
The Cash And Short Term Investments trend for Puma Biotechnology offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Puma Biotechnology is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Puma Biotechnology's Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Puma Biotechnology over the last few years. Short Term Investments is an account in the current assets section of Puma Biotechnology balance sheet. This account contains Puma Biotechnology investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Puma Biotechnology fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Puma Biotechnology's Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
Puma Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 86,715,127 | |
| Geometric Mean | 66,450,109 | |
| Coefficient Of Variation | 49.60 | |
| Mean Deviation | 28,946,351 | |
| Median | 83,948,000 | |
| Standard Deviation | 43,012,451 | |
| Sample Variance | 1850.1T | |
| Range | 193.1M | |
| R-Value | 0.27 | |
| Mean Square Error | 1830.9T | |
| R-Squared | 0.07 | |
| Significance | 0.30 | |
| Slope | 2,289,344 | |
| Total Sum of Squares | 29601.1T |
Puma Cash And Short Term Investments History
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company was founded in 2010 and is headquartered in Los Angeles, California. Puma Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 196 people. The stock overview for Puma Biotechnology summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/E of 18.52, P/B of 2.37, profit margin of 13.62%. Puma Biotechnology has market cap of 308.31 M, P/E of 18.52, ROE of 27.97%.
Methodology
Unless otherwise specified, financial data for Puma Biotechnology is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Puma (USA Stocks:PBYI) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Our reporting uses public filings and market reference sources and institutional disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Normalization procedures may introduce minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Puma Biotechnology may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Currently Active Assets on Macroaxis
More Resources for Puma Stock Analysis
A structured review of Puma Biotechnology often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Puma Biotechnology Stock. Outlined below are key reports that provide context for Puma Biotechnology Stock:Review Puma Biotechnology Correlation against competitors for Puma Biotechnology. This adds peer-relative context. For information on how to trade Puma Stock refer to our How to Trade Puma Stock guide.Analysis related to Puma Biotechnology should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Quarterly Earnings Growth -0.34 | Earnings Share 0.61 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
The market value of Puma Biotechnology is measured differently than book value, which reflects Puma accounting equity. Puma Biotechnology's market capitalization is 308.31 M. A P/B ratio of 2.37 indicates the market values Puma Biotechnology above its accounting book value. Enterprise value stands at 239.33 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Puma Biotechnology's intrinsic value and market price are different measures derived from different inputs. For Puma Biotechnology, key inputs include a P/E ratio of 18.52, a P/B ratio of 2.37, a profit margin of 13.62%, ROE of 27.97%. By contrast, market price reflects the level where buyers and sellers transact.